A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

BACKGROUND AND AIM: Ropeginterferon alfa‐2b is a novel mono‐pegylated, extra‐long‐acting interferon. It is administered infrequently and showed good tolerability and clinical activity for the chronic hepatitis B or C treatment in our previous Phase 2 clinical trials. This study aims to validate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chi‐Yi, Chuang, Wan‐Long, Qin, Albert, Zhang, Wen‐Hua, Zhu, Li‐Ying, Zhang, Guo‐Qiang, Chen, Jyh‐Jou, Lo, Ching‐Chu, Zhou, Xinmin, Mao, Xiaorong, Shang, Jia, Kuo, Hsing‐Tao, Xie, Wen, Chen, Chien‐Hung, Lo, Gin‐Ho, Jun, Dae W, Dang, Shuangsuo, Tsai, Chan‐Yen, Wang, Ting‐Fang, Lai, Hsin‐Hui, Tseng, Kuan‐Chiao, Huang, Yi‐Wen, Chen, Pei‐Jer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667409/
https://www.ncbi.nlm.nih.gov/pubmed/36406648
http://dx.doi.org/10.1002/jgh3.12825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667409/
https://www.ncbi.nlm.nih.gov/pubmed/36406648
http://dx.doi.org/10.1002/jgh3.12825

Ejemplares similares